MA35363B1 - Utilisation d'un composé organisation dans le traitement du syndrome de noonan - Google Patents
Utilisation d'un composé organisation dans le traitement du syndrome de noonanInfo
- Publication number
- MA35363B1 MA35363B1 MA36785A MA36785A MA35363B1 MA 35363 B1 MA35363 B1 MA 35363B1 MA 36785 A MA36785 A MA 36785A MA 36785 A MA36785 A MA 36785A MA 35363 B1 MA35363 B1 MA 35363B1
- Authority
- MA
- Morocco
- Prior art keywords
- noonan
- syndrome
- treating
- compound
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 206010029748 Noonan syndrome Diseases 0.000 title abstract 2
- 230000008520 organization Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000002372 labelling Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne l'utilisation d'un composé inhibiteur de la mek de formule (i), telle que définie ici, ou d'un sel pharmaceutiquement acceptable de celui-ci dans la préparation d'un médicament destiné à traiter un syndrome de noonan. L'invention concerne également un procédé de traitement d'un animal à sang chaud, et plus particulièrement un humain, atteint du syndrome de noonan, comprenant l'administration au dit animal d'une quantité thérapeutiquement efficace d'un composé inhibiteur de la mek de formule (i), telle que définie ici, ou d'un sel pharmaceutiquement acceptable de celui-ci. L'invention concerne en outre une composition pharmaceutique et un conditionnement commercial comprenant un composé de formule (i) ou un sel pharmaceutiquement acceptable de celui-ci, et une notice d'information ou autre étiquetage comprenant le mode d'emploi pour traiter le syndrome de noonan.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530128P | 2011-09-01 | 2011-09-01 | |
| PCT/US2012/052750 WO2013033133A1 (fr) | 2011-09-01 | 2012-08-29 | Utilisation d'un composé organique dans le traitement du syndrome de noonan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35363B1 true MA35363B1 (fr) | 2014-08-01 |
Family
ID=46826924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36785A MA35363B1 (fr) | 2011-09-01 | 2014-02-28 | Utilisation d'un composé organisation dans le traitement du syndrome de noonan |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9034909B2 (fr) |
| EP (1) | EP2750672A1 (fr) |
| JP (1) | JP2014528928A (fr) |
| KR (1) | KR20140068037A (fr) |
| CN (1) | CN103764134A (fr) |
| AU (1) | AU2012302106B2 (fr) |
| BR (1) | BR112014002885A2 (fr) |
| CA (1) | CA2845571A1 (fr) |
| CL (1) | CL2014000496A1 (fr) |
| IL (1) | IL231126A0 (fr) |
| MA (1) | MA35363B1 (fr) |
| MX (1) | MX2014002480A (fr) |
| PH (1) | PH12014500191A1 (fr) |
| RU (1) | RU2014112324A (fr) |
| SG (1) | SG2014005029A (fr) |
| TN (1) | TN2014000031A1 (fr) |
| WO (1) | WO2013033133A1 (fr) |
| ZA (1) | ZA201400460B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ586418A (en) | 2007-12-19 | 2012-09-28 | Cancer Rec Tech Ltd | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| JP5760010B2 (ja) | 2010-02-01 | 2015-08-05 | キャンサー・リサーチ・テクノロジー・リミテッド | １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用 |
| FI3702351T3 (fi) | 2012-10-19 | 2024-01-24 | Array Biopharma Inc | MEK-inhibiittorin käsittävä koostumus |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JP6670494B2 (ja) * | 2014-10-09 | 2020-03-25 | 国立大学法人 東京大学 | 心筋細胞の製造方法、心室型心筋細胞及びその製造方法、並びにスクリーニング方法 |
| EP3712133B1 (fr) | 2017-11-14 | 2025-12-24 | Shenzhen TargetRx, Inc. | Composé de benzimidazole substitué et composition le comprenant |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100984595B1 (ko) * | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체 |
| WO2008022335A2 (fr) * | 2006-08-18 | 2008-02-21 | The Brigham And Women's Hospital, Inc. | Diagnostic et traitement du syndrome de noonan et des troubles néoplasiques |
| WO2009135000A2 (fr) * | 2008-04-30 | 2009-11-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibition de la protéine tyrosine phosphatase shp2/ptpn11 par nsc-117199 et analogues |
-
2012
- 2012-08-29 KR KR1020147005039A patent/KR20140068037A/ko not_active Withdrawn
- 2012-08-29 CN CN201280042502.XA patent/CN103764134A/zh active Pending
- 2012-08-29 PH PH1/2014/500191A patent/PH12014500191A1/en unknown
- 2012-08-29 JP JP2014528530A patent/JP2014528928A/ja active Pending
- 2012-08-29 RU RU2014112324/15A patent/RU2014112324A/ru not_active Application Discontinuation
- 2012-08-29 SG SG2014005029A patent/SG2014005029A/en unknown
- 2012-08-29 CA CA2845571A patent/CA2845571A1/fr not_active Abandoned
- 2012-08-29 MX MX2014002480A patent/MX2014002480A/es unknown
- 2012-08-29 AU AU2012302106A patent/AU2012302106B2/en not_active Ceased
- 2012-08-29 BR BR112014002885A patent/BR112014002885A2/pt not_active IP Right Cessation
- 2012-08-29 EP EP12756614.9A patent/EP2750672A1/fr not_active Withdrawn
- 2012-08-29 WO PCT/US2012/052750 patent/WO2013033133A1/fr not_active Ceased
- 2012-08-29 US US14/239,165 patent/US9034909B2/en not_active Expired - Fee Related
-
2014
- 2014-01-21 TN TNP2014000031A patent/TN2014000031A1/en unknown
- 2014-01-21 ZA ZA2014/00460A patent/ZA201400460B/en unknown
- 2014-02-24 IL IL231126A patent/IL231126A0/en unknown
- 2014-02-28 MA MA36785A patent/MA35363B1/fr unknown
- 2014-02-28 CL CL2014000496A patent/CL2014000496A1/es unknown
-
2015
- 2015-05-12 US US14/709,607 patent/US20150320725A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TN2014000031A1 (en) | 2015-07-01 |
| CA2845571A1 (fr) | 2013-03-07 |
| NZ620542A (en) | 2014-12-24 |
| WO2013033133A1 (fr) | 2013-03-07 |
| PH12014500191A1 (en) | 2014-03-03 |
| US9034909B2 (en) | 2015-05-19 |
| ZA201400460B (en) | 2014-11-26 |
| CL2014000496A1 (es) | 2014-09-26 |
| JP2014528928A (ja) | 2014-10-30 |
| KR20140068037A (ko) | 2014-06-05 |
| AU2012302106A1 (en) | 2014-03-06 |
| CN103764134A (zh) | 2014-04-30 |
| RU2014112324A (ru) | 2015-10-10 |
| BR112014002885A2 (pt) | 2017-02-21 |
| MX2014002480A (es) | 2014-03-27 |
| AU2012302106B2 (en) | 2015-04-09 |
| SG2014005029A (en) | 2014-03-28 |
| US20150320725A1 (en) | 2015-11-12 |
| IL231126A0 (en) | 2014-03-31 |
| EP2750672A1 (fr) | 2014-07-09 |
| US20140200249A1 (en) | 2014-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35363B1 (fr) | Utilisation d'un composé organisation dans le traitement du syndrome de noonan | |
| MA30476B1 (fr) | Derives de type cyclohexylpyrazole-lactame comme inhibiteurs de la 11-beta-hydroxysteroïde deshydrogenase de type 1 | |
| MA38534A1 (fr) | Compositions synergiques comprenant le (2s)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl)ethoxy)phenyl)propanoate et des agents, par ex. Inhibiteurs de dipeptidyl peptidase-4, biguanide et/ou statines pour une utilisation dans la dyslipidémie | |
| MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
| MA38385A1 (fr) | Nouvelle composition pour la stéatose hépatique non alcoolique (nafld) | |
| MA32171B1 (fr) | Compose heterocyclique | |
| AU2016233257B2 (en) | Fixed dose combinations comprising ETC1002 and one or more statins for treating or reducing cardiovascular risk | |
| MA31496B1 (fr) | Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c | |
| NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
| BR112014003981A2 (pt) | compostos de pirimido-piridazinona e seu uso | |
| MA27692A1 (fr) | Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments | |
| MA37891A1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
| EA200971041A1 (ru) | Новые пептидные ингибиторы репликации вируса гепатита с | |
| MA32458B1 (fr) | Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer | |
| MA37886A1 (fr) | Nouvelles pyridinones bicycliques | |
| MA38358A1 (fr) | Formulations de composés organiques | |
| MA38694B1 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
| MA34554B1 (fr) | Combinaisons pharmaceutiques | |
| EP2307007A1 (fr) | Modulateurs du récepteur de sphingosine 1 phosphate et leur utilisation pour le traitement de l'inflammation musculaire | |
| Oliveira et al. | HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015) | |
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| US9968592B2 (en) | Dyslipidemia therapeutic agent | |
| MA33979B1 (fr) | Piperazines en tant qu'agents antipaludiques | |
| MA32128B1 (fr) | Association entre un sel de bis-thiazolium ou l'un de ses precurseurs et l'artémisinine ou l'un de ses derives pour le traitement du paludisme severe | |
| Ducobu et al. | Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia |